Panobacumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Pseudomonas aeruginosa serotype IATS O11
Clinical data
ATC code	none
Identifiers
CAS Number	885053-97-4^N
ChemSpider	none
UNII	62B4OXU259
Chemical and physical data
Formula	C₃₈₇₁₄H₆₀₁₈₉N₁₀₆₃₇O₁₂₁₈₇S₃₂₂
Molar mass	879959.96 g·mol⁻¹
^NY (what is this?) (verify)

Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.^[1]

It is a fully human pentameric IgM antibody with a mouse J chain.^[1]

Development

Panobacumab is being developed by Aridis Pharmaceuticals. As of November 15th it is in phase 2 clinical trials. The originator was Berna Biotech.^[2]

The mechanism of action is as a lipopolysaccharide inhibitor.^[2]

References

Human	Efungumab^†

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab^§ Bamlanivimab^† (+etesevimab)^† Bebtelovimab^§ Casirivimab^† (+imdevimab) Cilgavimab^† (+tixagevimab)^† Diridavumab^§ Etesevimab^† Exbivirumab^§ Foravirumab^§ Imdevimab^† (+casirivimab) Libivirumab^§ Maftivimab Nirsevimab^† Odesivimab Rafivirumab^§ Regavirumab^§ Regdanvimab Sevirumab^† Sotrovimab Suptavumab Tixagevimab^† (+cilgavimab)^† Tuvirumab^§
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab^†
Humanized	Felvizumab^§ Lenvervimab^† Motavizumab^† Palivizumab Suvizumab^§

Human	Nebacumab Panobacumab^§ Raxibacumab
Mouse	Edobacomab^§
Chimeric	Pagibaximab^†
Humanized	Tefibazumab^†

Human	Actoxumab^§ Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab^§